Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors

Diagnostic Pathology

Volumn 7, Issue 1, 2012, Pages

  Hewedi, Iman H ^a   Radwan, Nehal A ^a   Shash, Lobna S ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Leiomyosarcoma; P53; Pr; Stump; Uterine smooth muscle tumor

Indexed keywords

PROGESTERONE RECEPTOR; PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CHEMISTRY; CHI SQUARE DISTRIBUTION; DIFFERENTIAL DIAGNOSIS; EGYPT; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY; UTERUS CANCER;

CHI-SQUARE DISTRIBUTION; DIAGNOSIS, DIFFERENTIAL; EGYPT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS;

EID: 84855368569     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-7-1     Document Type: Article

References (25)

1. Zaloudek CJ, Hendrickson MR, Soslow RA. Mesenchymal tumors of the uterus. Blaustein's Pathology of the Female Genital Tract 2011, 453-527. Springer New York, R. Kurman RJ, Ellenson LH, Ronnett BM, 6.
2. Rammeh-Rommani S, Mokni M, Stita W, Trabelsi A, Hamissa S, Sriha B, Tahar-Yacoubi M. J Gynecol Obstet Biol Reprot 2005, 34:568-7.
3. Ünver NU, Acikalin MF, Öner T, Ciftci E, Ozalp SS, Colak E. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors. Arch Gynecol Obstet 2011, 284(2):483-90. 10.1007/s00404-010-1690-z, 20878171.
4. O'neill CI, Mcbride HA, Connolly LE, Mccluggage WG. Histopathology 2007, 50:851-8. 10.1111/j.1365-2559.2007.02699.x, 17543074.
5. Gökaslan H, Turkeri L, Kavak ZN, Eren F, Sismanoglu A, Ilvan S, et al. Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors. Gynecol Obstet Invest 2005, 59:36-40. 10.1159/000080933, 15377824.
6. Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Mayerhofer K. Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors. Fertil Steril 2004, 81:1062-6. 10.1016/j.fertnstert.2003.08.043, 15066464.
7. Mittal K, Demopoulos RI. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum Pathol 2001, 32:984-7. 10.1053/hupa.2001.27113, 11567229.
8. Zhai YL, Kobayashi Y, Mori A, Orii A, Nikaido T, Konishi I, et al. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol 1999, 18:20-8. 10.1097/00004347-199901000-00004, 9891238.
9. Mayerhofer K, Obermair A, Windbichler G, Petru E, Kaider A, Hefler L, et al. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol 1999, 74:196-201. 10.1006/gyno.1999.5436, 10419731.
10. Al-Nafussi A. Uterine smooth-muscle tumours: practical approach to diagnosis. Curr Diagn Pathol 2004, 10:140-56.
11. Watanabe K, Suzuki T. Uterine leiomyoma versus leiomyosarcoma: a new attempt at differential diagnosis based on their cellular characteristics. Histopathology 2006, 48:563-8. 10.1111/j.1365-2559.2006.02368.x, 16623782.
12. Petrovic D, Babic D, Forko JI, Martinac I. Expression of Ki-67, p53 and progesterone receptors in uterine smooth muscle tumors: diagnostic value. Coll Antropol 2010, 34(1):93-7.
13. Buttram VC, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981, 36:433-45.
14. Kawaguchi K, Fujii S, Konishi I, Nanbu Y, Nonogaki H, Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 1989, 160:637-41.
15. Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Leodolter S, Mayerhofer K. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. Anticancer Res 2003, 23:729-32.
16. Soper JT, McCarty KS, Creasman WT, McCarty KS, Clarke-Pearson DL. Cytoplasmic estrogen and progesterone receptor content of uterine sarcomas. Am J Obstet Gynecol 1984, 150:342-8.
17. Akhan SE, Yavuz E, Tecer A, yibozkurt CA, Topuz S, Tuzlali{dotless} S, et al. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas: A clinicopathologic study. Gynecol Oncol 2005, 99:36-42. 10.1016/j.ygyno.2005.05.019, 15992918.
18. Zalondex CJ, Hendricksen CJ. Mesenchymal tumors of the uterus. Blaustein''s pathology of the female genital tract 2002, 561-615. Spinger, New York, Kurman RJ, fifth.
19. Westhof G, Bader W, Greiner-Mai E, Hartzmann W. Comparison of cytosolic p53 protein levels in the female genital tract and breast, and their tumors. Tumor Biol 2000, 21:123-134.
20. De Vos S, Wilczynski SP, Fleishhacker M, Koeffler P. p53 alterations in uterine leiomyosarcomas versus leiomyomas. Gynecol Oncol 1994, 54:205-208. 10.1006/gyno.1994.1194, 8063247.
21. Hong T, Schimada Y, Uchida S, Itami A, Li Z, Ding Y, Kaganoi J, Komoto I, Sakurai T, Imamura M. Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma. Int J Mol Med 2001, 8:141-148.
22. Jeffers MD, Farquharson MA, Richmond JA, McNicol AM. p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumors of the uterine corpus. J Pathol 1995, 177:65-70. 10.1002/path.1711770111, 7472782.
23. Nordal RR, Kristensen GB, Stenwig AE, Trope CG, Nesland JM. Immunohistochemical analysis of p53 protein in uterine sarcomas. Gynecol Oncol 1998, 70:45-48. 10.1006/gyno.1998.5034, 9698472.
24. Wang M, Xu Y, Zhang T. Smooth muscle neoplasms of the uterus - A 51 cases study. Zhonghua Bing Li Xue Za Zhi 1996, 25:263-265.
25. Kayser K, Zink S, Schneider T, Dienemann H, Andre S, Kaltner H, Schuring MP, Zick Y, Gabius HJ. Benign metastasizing leiomyoma of the uterus: Documentation of clinical, immunohistochemical and lectin-histochemical data of ten cases. Virchows Arch 2000, 473:284-292.